In the context of possible modes of action of IFN-β as an immunomodulatory therapy in MS, it is worth noting that IGFBPs have been suggested to be involved in regulation of remyelination and increased levels of IGFBP4 in MS lesions were reported [54]. Here, IGFBP4 is linked to myeloid sarcoma.